Title:
抗体依存性細胞傷害（ＡＤＣＣ）を増強する方法
Document Type and Number:
Japanese Patent JP2022512747
Kind Code:
A
Abstract:
ヘルペスウイルスエントリーメディエーター（ＨＶＥＭ）アゴニストを用いて、対象において感染性物質のワクチンに対する中和抗体応答よりも抗体依存性細胞傷害（ＡＤＣＣ）抗体応答を優先的に増強する方法および関連する組成物。
Inventors:
Betsy Herold
Claire Burn
Claire Burn
Application Number:
JP2021521246A
Publication Date:
February 07, 2022
Filing Date:
October 17, 2019
Export Citation:
Assignee:
ALBERT EINSTEIN COLLEGE OF MEDICINE
International Classes:
A61K39/00; A61K38/17; A61P37/02; A61P37/04
Domestic Patent References:
| JP2017510262A | 2017-04-13 |
Foreign References:
| US20100136061A1 | 2010-06-03 | |||
| WO2017068180A1 | 2017-04-27 |
Other References:
KANODIA, SHREYA ET AL.: "Expression of LIGHT/TNFSF14 Combined withVaccination against Human Papillomavirus Type 16 E7 Induces", CANCER RES, vol. 70, no. 10, JPN6023035896, 2010, pages 3955 - 3964, XP055419383, ISSN: 0005144831, DOI: 10.1158/0008-5472.CAN-09-3773
PETRO, CHRISTOPHER D. ET AL.: "HSV-2 ΔgD elicits FcγR-effectorantibodies that protect against clinical isolates", JCI INSIGHT, vol. 1(12):e88529, JPN6023035895, 2016, pages 1 - 15, ISSN: 0005144832
PETRO, CHRISTOPHER D. ET AL.: "HSV-2 ΔgD elicits FcγR-effectorantibodies that protect against clinical isolates", JCI INSIGHT, vol. 1(12):e88529, JPN6023035895, 2016, pages 1 - 15, ISSN: 0005144832
Attorney, Agent or Firm:
Yamato Kento
Norifumi Tomita
Fumio Inai
Manami Sasakura
Norifumi Tomita
Fumio Inai
Manami Sasakura
Previous Patent: Interleukin-10 polypeptide complex, its dimer, and their use
Next Patent: Abitsuzumab for the treatment of colorectal cancer
Next Patent: Abitsuzumab for the treatment of colorectal cancer